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Abstract Synaptojanin1, the major constitutively active
PtdInsP3 5-phosphatase activity in rat brain, is one of two
closely related proteins both extensively spliced in their C-
terminal proline rich domain. We describe here the discovery of a
novel splice variant of synaptojanin1 which misses the major N-
terminal part of the SAC1 domain. This vSAC-synaptojanin1 is
expressed in rat brain tissue as shown by Northern and Western
analysis. However, the deletion of the SAC1 domain does not
alter PtdInsP3 5-phosphatase activity demonstrating that the
SAC1 domain is not necessary for catalytic function.
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1. Introduction
Inositol polyphosphate 5-phosphatases are enzymes which
remove phosphates at the 5-hydroxyl position of phosphoino-
sitides and inositol polyphosphates. Both substrates and prod-
ucts are implicated in signal transduction processes suggesting
that these 5-phosphatases might play a role in controlling
these events [1]. In particular, two 5-phosphatases have been
the focus of recent investigations, SHIP and synaptojanin [2^
6]. The latter has been shown to be the principal constitutively
active PtdInsP3 5-phosphatase in brain tissue suggesting that
it might be involved in the regulation of phosphoinositide 3-
kinase dependent signalling [7]. Synaptojanin is also supposed
to be part of the machinery which controls or modulates
synaptic vesicle transport due to its unique tissue distribution
and the subcellular localisation of binding partners [1,4,8^12].
Thus, synaptojanin seems to participate in the phosphoinosi-
tide 3-kinase dependent membrane tra⁄c in neuronal cells [1].
To date two distinct, but highly conserved gene products
termed synaptojanin1 and synaptojanin2 have been identi¢ed
[4,11,12]. We have now mapped the synaptojanin1 gene to
mouse chromosome X, region D (R. Woscholski and J.A.
Williamson, unpublished observation). As such, it will be of
interest to know whether this is re£ected in any autosomal
disorders. Synaptojanin2 has yet to be mapped. Both of these
genes are transcribed to produce multiple processed tran-
scripts that re£ect splice sites in the C-terminal proline rich
domain [4,13,14]. These forms seem to be di¡erentially ex-
pressed in neuronal cells at di¡erent developmental stages
and localised to distinct subcellular compartments [4,11,12].
One form, a particular splice form of synaptojanin1 contain-
ing a 16 amino acid insert in the proline rich domain, is the
major transcript in the brain and accounts for nearly all of the
constitutively active PtdInsP3 5-phosphatase [7]. We describe
here the discovery of a novel splice form of synaptojanin1
characterised by a truncated N-terminal SAC domain. Expres-
sion of this variant demonstrates that the SAC domain is not
necessary for catalytic function.
2. Materials and methods
2.1. Cloning of synaptojanin splice variant
Synaptojanin1 was puri¢ed from rat brain tissue and subjected to
microsequencing as described [15]. Degenerate primers were then de-
signed for a 44 aa peptide covering the core 5-phosphatase domain
(K743^Y784). These primers were then used to amplify the corre-
sponding cDNA from a rat brain library (Stratagene) by polymerase
chain reaction (PCR). A PCR product sequenced and found to be
identical to the sequence obtained by microsequencing of the puri¢ed
synaptojanin1 [15] was then random labelled and employed in a screen
using the same library. We have described elsewhere the identity of
the puri¢ed synaptojanin [7]. However, in addition we isolated an N-
terminal truncated synaptojanin1 missing almost three quarters of the
N-terminal SAC1 domain which is referred to here as vSAC-synap-
tojanin1 (accession number AJ006855).
2.2. Northern blot and sequence analysis
Sequencing was performed on an ABI Prism Sequencer (Perkin
Elmer) using the ABI Prism £uorescence labelling kit. Northern blots
of di¡erent tissues were obtained from Clontech. The blots were
washed in hybridisation bu¡er (Church’s mix) at 50‡C. The probes
employed were either end or random labelled and employed at the
indicated temperature using Church’s mix. The synaptojanin1 com-
mon probe was generated by cutting out the coding sequence with
HindIII and NheI (2623 bp) and was then used for random labelling,
while the vSAC-synaptojanin1 speci¢c probe was generated by cutting
out a 165 bp fragment from the vSAC-synaptojanin1 clone using
EcoRI and SphI and subsequently end labelled. The blots were then
visualised by autoradiography or phosphorimager scanning.
2.3. Antibodies and protein analysis
Antibodies against the insert and C-terminal region were raised and
employed for Western blotting as described [7]. Rat brains were re-
moved immediately and frozen in liquid nitrogen. Soluble and partic-
ulate fractions were obtained as described before [15]. Protein and 5-
phosphatase activity were determined as previously documented [15].
3. Results and discussion
3.1. Cloning of a novel synaptojanin1 splice variant
We recently puri¢ed the constitutively active PtdInsP3 5-
phosphatase from rat brain [15] which then was subjected to
microsequencing. The resulting peptide sequence was found to
be novel, but related to the inositol polyphosphate 5-phospha-
tase core sequences [7], indicating that the puri¢ed PtdInsP3 5-
phosphatase has to be a novel member of the widening ino-
sitol polyphosphate 5-phosphatase family [1]. While the clon-
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ing was in progress McPherson et al. [4] cloned a novel 5-
phosphatase, called synaptojanin (now renamed synaptoja-
nin1) which was identical in its sequence to the peptide and
cDNA sequence obtained at that time. However, all clones
had two base pair changes (A1904G and A2883G) and pos-
sessed a unique 16 aa splice insert at the 3P end of the open
reading frame. Thus, it seemed that the puri¢ed PtdInsP3 5-
phosphatase is identical with synaptojanin1 which was then
subsequently proven by immunoprecipitation experiments us-
ing speci¢c antibodies and employment of recombinant syn-
aptojanin1 [7]. Although all clones were identical to the de-
scribed synaptojanin1 sequence, one clone seemed to contain
a unique 5P truncation (see Fig. 1). This particular clone had a
stretch of about 200 bp unique sequence at the 5P end of the
clone between the critical EcoRI site (cloning site of the li-
brary) and the known coding synaptojanin1 sequence suggest-
ing that this particular synaptojanin1 clone might to be a
possible splice variant. This N-terminal truncated synaptoja-
nin1 missing almost three quarters of the N-terminal SAC1
domain [4] will from now on be referred to as vSAC-synap-
tojanin1.
In order to determine if vSAC-synaptojanin1 is expressed in
vivo a Northern blot analysis was carried out. Probes were
designed either to be unique for the vSAC-synaptojanin1
splice variant (probe: vSAC-synaptojanin1 speci¢c consisting
of the ¢rst 200 bp from the 5P non-coding region) or to be
void of any unique sequence (probe: common synaptojanin1;
comprising 2.6 kb of coding region). As shown in Fig. 2, the
Northern blot analysis revealed that the synaptojanin1 speci¢c
probe hybridised in brain tissue with several di¡erently sized
mRNAs. A much shorter mRNA product was detected in
lung tissue. However, as shown before [4,11] synaptojanin1
seems to be expressed at highest levels in brain. The synapto-
janin1 common probe detected several messages in rat brain
(arrows in Fig. 2) as compared to lung and heart tissue where
only the shorter message was detected. The vSAC-synaptoja-
nin1 speci¢c message detected in principle only one message
per tissue but of di¡erent size: the highest level in lung fol-
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Fig. 1. Sequence of the 5P vSAC-synaptojanin1 clone. The ¢rst 360 bp of the vSAC-synaptojanin1 clone are shown. The novel sequence and
its translation is boxed; the underlined translated sequence represents the start of the coding sequence. The EcoRI site used for the creation of
the library is shown in italics.
Fig. 2. Northern blot analysis of rat tissues. Probes against the unique 5P end of the vSAC-synaptojanin1 splice variant (left) and the coding
synaptojanin1 sequence (right) were prepared as described in Section 2. The probes were then hybridised with the rat brain tissue blot (Clon-
tech) according to the manufacturer’s instructions at 50‡C. Labelled bands were visualised by autoradiography. The position of molecular
weight markers (from top to bottom: 9.5, 7.5, 4.4, 2.4 and 1.35 kb) is indicated between the two autoradiographs.
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lowed by brain, testis and heart. Since the synaptojanin1 spe-
ci¢c probe and the vSAC-synaptojanin1 speci¢c probe de-
tected a similar sized message in brain (middle arrow in Fig.
2) it can be concluded that the N-terminal truncated synapto-
janin1 splice variant is detectable as a 7 kb mRNA in rat
brain tissue.
3.2. The vSAC-synaptojanin1 splice variant is expressed in rat
brain tissue
Although the vSAC-synaptojanin1 speci¢c cDNA probe
detected a transcript in lung tissue (Fig. 2), Western blots
(not shown) revealed that there is no detectable protein bear-
ing the 16 aa insert (the antigen for the synaptojanin1 anti-
body) [7]. Thus, synaptojanin1and vSAC-synaptojanin1 with
the 16 aa insert splice variation are not present at signi¢cant
levels in other tissues. Since antibodies raised against the C-
terminus as well as the 16 aa splice insert of synaptojanin1 did
not detect protein in the other tested tissues (data not shown),
detectable levels of synaptojanin1 seem to be con¢ned to neu-
ronal tissue. Thus, we tested whether rat brain tissue contains
smaller synaptojanin forms by Western blot. As shown in Fig.
3, recombinant vSAC-synaptojanin1 matches one of the
bands in rat brain cytosol. Taking all these observations to-
gether it is likely that vSAC-synaptojanin1 is expressed in
brain although not at high levels compared to synaptojanin1
itself.
Since it has been argued that the SAC domain might play a
role in the regulation of the activity [4,16], we investigated
whether this particular splice form has altered catalytic prop-
erties. As shown in Fig. 4, the N-terminal deletion of the SAC
domain did not a¡ect the speci¢c activity suggesting that the
SAC domain is not necessary for catalytic activity. The data
presented indicate that the novel splice variant vSAC-synap-
tojanin1 is expressed in rat brain tissue based on Northern
and Western blot analysis. However, N-terminal deletion does
not alter the intrinsic catalytic activity demonstrating that this
domain is not essential for the 5-phosphatase activity. The
identi¢cation of this novel vSAC-synaptojanin1 provides evi-
dence that an alternative 5P splice variation occurs in synap-
tojanin1. This splice product is weakly expressed as compared
to the previously characterised synaptojanin1 in brain tissue.
But although this vSAC-synaptojanin1 seems to be not abun-
dant with respect to expression or activity, it cannot be ruled
out that this splice form might be more extensively expressed
in development or particular cell types. Ultimately the poten-
tial role of vSAC-synaptojanin1 may well be derived from
elucidation of the function of the SAC domain. Evidently
deletion of this domain may retrieve speci¢c constraints on
activity or localisation. This remains to be determined.
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Fig. 3. Comparison of recombinant vSAC-synaptojanin1 and synap-
tojanin1 forms by Western blot. vSAC-synaptojanin1 was expressed
in COS cells. COS cell extracts (lanes 1 and 3) and rat brain cytosol
(lanes 2 and 4) were then separated by SDS polyacrylamide gel elec-
trophoresis and blotted onto PVDF membranes. The blot was then
incubated with antibodies raised against synaptojanin1 (insert). Un-
speci¢c binding was checked by incubating in the presence of com-
peting peptide (lanes 1 and 2).
Fig. 4. Comparison of PtdInsP3 5-phosphatase activities of recombi-
nant vSAC-synaptojanin1 and synaptojanin1. vSAC-synaptojanin1
and synaptojanin1 were expressed in COS cells and immunoprecipi-
tated using the insert speci¢c synaptojanin1 antibody. Expression
levels were checked by Western blot (insert speci¢c antibody) using
crude extracts. Immunoprecipitates were subjected to a PtdInsP3 5-
phosphatase assay. Quanti¢cation of the assay was done by phos-
phorimager; data are shown as relative activity. This is one of two
similar experiments.
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